FY26 COPS Technology and Equipment Program

Under the Paul Coverdell Forensic Science Improvements Grant Program, state administering agencies (SAAs) may be eligible and apply for both formula and competitive funds. This NOFO is ONLY for formula funds. An applicant seeking to apply for Coverdell competitive funds (consistent with 34 U.S.C. § 10563(a)(2)) that are available to eligible states and units of local government would need to apply separately under BJA’s FY 2026 Paul Coverdell Forensic Science Improvement—Competitive Grants Program NOFO.

This is a notice of funding opportunity (NOFO) for the BJA FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR) — Competitive Grants Program. This opportunity will increase capacity of states and units of local government with existing crime laboratories to process DNA samples for entry into the Combined DNA Index System (CODIS). The purpose of the CEBR Competitive Program is to maximize the effective utilization of DNA technology to strengthen evidence-based criminal justice responses. The priorities of the CEBR Competitive Program are (1) to use DNA technology to increase the capacity and/or efficiency of publicly funded forensic DNA laboratories to conduct analysis of DNA samples for entry into CODIS and (2) implementing Rapid DNA in the booking station(s) in eligible jurisdictions. The program is designed to fairly and efficiently prioritize jurisdictions facing operational challenges by considering key performance measures reported by publicly funded forensic DNA laboratories. This program is for Competitive funding only. The BJA FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR) — Formula Grants Program for formula funding will post at a later date. Eligible agencies may apply for both Competitive and Formula CEBR Funding.

The Office of Justice Programs (OJP) is committed to advancing work that furthers the U.S. Department of Justice’s (DOJ) mission to keep our country safe and secure and uphold the rule of law and protect the rights of American citizens. OJP provides federal leadership, funding, and other critical resources to directly support law enforcement, combat violent crime, protect American children, provide services to American crime victims, and address public safety challenges, including human trafficking and the opioid crisis. This NOFO, as authorized by the Bipartisan Safer Communities Act of 2022, will provide funding for the creation or enhancement of state crisis intervention court proceedings and related programs or initiatives, including extreme risk protection order (ERPO) programs, as well as mental health courts, drug courts, and veterans treatment courts.

This is a notice of funding opportunity (NOFO) for the OJJDP FY 2026 Multistate Mentoring Programs. This opportunity supports the implementation and delivery of mentoring services to youth populations that are at risk or high risk for delinquency, victimization, and going into the juvenile justice system. Mentoring services can be one-on-one, group, peer, or a combination of these types.

This is a notice of funding opportunity (NOFO) for the BJA FY 2026 National Center for Veterans Justice. This opportunity will establish a national center to provide specialized support to state, local, and tribal criminal justice agencies; treatment and service providers; courts; corrections systems; and community supervision agencies to effectively support and respond to the needs of veterans across the justice system, improve outcomes, and strengthen public safety. The Center will serve as a one stop shop to address critical gaps in veteran identification, cross-system coordination, and implementation of evidence-based interventions by providing criminal justice professionals with specialized tools, training, and technical assistance on military culture, combat trauma, military sexual trauma (MST), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and other veteran-specific considerations. Providing resources and specialized technical assistance through a centralized location and entity is essential to effectively supporting veterans whose needs require coordination across multiple systems, including criminal justice, Department of Veterans Affairs (VA), behavioral health, and social service systems that operate under distinct legal frameworks and institutional priorities.

This is a notice of funding opportunity (NOFO) for the BJA FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR)—Formula Grants Program. This opportunity will support states and units of local government with existing crime laboratories that conduct DNA analysis to process, and/or to increase the capacity to process, more DNA samples for entry into the Combined DNA Index System (CODIS), thereby helping to reduce the number of forensic DNA and DNA database samples awaiting analysis and/or to prevent a backlog of forensic and database DNA samples.

Expected Outcome: This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as: The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scaling The absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes: By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a firmware stack (scheduler, controller, compiler), validated via hardware-agnostic benchmarks and hybrid photonic-HPC applications demonstrating classical-quantum crossover By 2030, delivery of a full-stack, high-connectivity photonic quantum computer, with modular scalability, integrated…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Outcome: Proposals are expected to contribute to all following points: The projects must fulfil the performance targets, at the cell and system level, corresponding to the specific targeted application, to be specified in the proposal. Appropriate KPI must be defined for the energy density (volumetric and gravimetric), Power density and C-rate, number of cycles and cost defined under operational conditions. Boost EU competitiveness in next-generation battery technologies for mobility applications. Develop pilot manufacturing capability for next generation lithium-based batteries. Strengthen the EU battery value chain, including new manufacturing equipment, automation, and scalable production processes. Advance the understanding of next-generation battery interfaces at an industrial scale, ensuring manufacturability, durability, and cost-effectiveness. In the case of aviation, the battery requirements should be compatible at minimum with EASA CS.23 (level 4), CS.27 and preferably with CS.25 categories. Scope: This topic will support the scaling-up of next generation (i.e., beyond generation 3) lithium-based batteries (e.g., semi and all-solid state, generation5) from cell…

Expected Outcome: This flagship pilot is the culmination of the entire activity catalogue carried out by the CCAM Partnership since its launch in 2021. It will combine in one project the most promising CCAM use-cases across three key domains, with the technological advancements from all its R&I clusters [1] supporting and enabling CCAM systems and services towards market uptake. This action is expected to contribute to all the following outcomes: Large-scale demonstrations of inclusive, user-oriented, and well-integrated CCAM systems and services for people and goods in mixed traffic through Field Operational Tests (FOTs), Technology Pilots, and Living Labs, building upon advanced and emerging SAE Level 2 systems to move towards SAE Level 3 and 4 functionalities, at multiple test sites and corridors showcasing CCAM potential [2] , for a minimum of 12 months. Validation of enabling technologies that facilitate the extension of Operational Design Domains (ODDs) in large-scale operations and enhance perception performance under poor lighting and adverse weather conditions in large-scale demonstrations and pilots. Assessment of deployment readiness and demonstration of technological…